0.04
+0.0047(+13.35%)
Currency In USD
| Previous Close | 0.04 |
| Open | 0.04 |
| Day High | 0.04 |
| Day Low | 0.04 |
| 52-Week High | 0.04 |
| 52-Week Low | 0.04 |
| Volume | 100 |
| Average Volume | 31,919.38 |
| Market Cap | 11.66M |
| PE | -0.02 |
| EPS | -1.73 |
| Moving Average 50 Days | 0.05 |
| Moving Average 200 Days | 0.05 |
| Change | 0 |
Cingulate Presents Positive Phase 3 Results for CTx-1301 Demonstrating Statistically Significant Efficacy and Entire Active-Day Symptom Control
GlobeNewswire Inc.
Oct 28, 2025 12:00 PM GMT
Once-daily formulation of dexmethylphenidate achieved primary endpoint (p < 0.001) with consistent symptom relief up to 12 hours post-doseKANSAS CITY, Kan., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical compan
Cingulate’s Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting
GlobeNewswire Inc.
Oct 23, 2025 8:45 PM GMT
Presentation by ADHD expert Dr. Ann Childress to highlight Phase 3 findings supporting the potential for true, entire active-day symptom controlKANSAS CITY, Kan., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical
FDA Accepts Cingulate’s New Drug Application for CTx-1301 in Attention-Deficit/Hyperactivity Disorder (ADHD) and sets a May 31, 2026 PDUFA Date
GlobeNewswire Inc.
Oct 14, 2025 12:00 PM GMT
Once-daily Precision Timed Release™ (PTR™) stimulant designed to deliver rapid onset of effect and entire active-day duration NDA accepted under the FDA’s 505(b)(2) regulatory pathway KANSAS CITY, Kan., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Cingulate I